title: Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
abstract: OBJECTIVE
  To determine the potential effectiveness of a behavioural weight control programme including physical exercise in the prevention of antipsychotic-induced weight gain and associated comorbid conditions in outpatients with schizophrenia and mood disorders.
  
  
  METHODS
  A prospective, comparative, open and naturalistic study was carried out for a total of 110 patients with schizophrenia, schizoaffective or bipolar disorders (DSM-IV), on treatment with atypical antipsychotics. Of these, 59 patients participated in an 18 month weight control programme that included an educational activity about dietary and physical activity counselling as well as a structured, supervised, facility-based exercise programme. The control group consisted of 51 patients with the same baseline characteristics who did not receive the clinical programme. Anthropometric measurements, plasma lipid-lipoprotein profile, and fasting plasma glucose concentrations were assessed at 11 time-points over the study. In addition, serum concentrations of prolactin, thyrotropin-stimulating hormone (TSH), and glycated haemoglobin (HbA1c) were assessed at four time-points. Finally, the Clinical Global Impression scale (CGI), the Brief Psychiatric Rating Scale (BPRS) and the Short Form (SF)-36 Health Survey were used.
  
  
  RESULTS
  The adherence rate of patients was 85%, both in the active and in the control group. Whereas the control group experienced a significant increase in bodyweight (4.1%), body mass index (BMI; 5.5%) and waist circumference (WC; 4.2%), the active group significantly reduced their bodyweight (-3.5%), BMI (-4.4%), and WC (-4.6%) at the study end-point. In addition, a significant increase in low-density lipoprotein (LDL)-cholesterol (14.8%) and in triglyceride concentrations (12.3%) was observed at month 18 in the control group. In contrast, high-density lipoprotein-cholesterol (HDL) significantly increased (21.4%), and LDL cholesterol (-13.7%), triglycerides (-26.2%), total cholesterol (-12.1%), fasting glucose concentrations (-12.0%), and HbA1c (-11.4%) significantly decreased compared to baseline in the active group. No significant changes were observed regarding serum concentrations of prolactin and TSH during the study. In regard to the changes observed in psychological measures, no between-group differences were seen in the clinical ratings of CGI and BPRS. However, the SF-36 showed that physical health was improved only for subjects in the active group at months 12 and 18 compared to baseline (p<0.05), and mental health was significantly improved for both groups at months 12 and 18 compared to baseline.
  
  
  CONCLUSIONS
  Bodyweight and metabolic risk profile in patients receiving atypical antipsychotic medications can be effectively managed with a weight control programme including physical activity.
authors.affiliation: Centre Hospitalier Affilié Universitaire de Québec, Hôpital de l'Enfant-Jésus and Centre Hospitalier Robert-Giffard, Quebec City, Quebec, Canada.
authors.forename: Marie-Josée
authors.initials: MJ
authors.lastname: Poulin
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Chaput
authors.forename: Véronique
authors.initials: V
authors.lastname: Simard
authors.forename: Pierre
authors.initials: P
authors.lastname: Vincent
authors.forename: Joëlle
authors.initials: J
authors.lastname: Bernier
authors.forename: Yvan
authors.initials: Y
authors.lastname: Gauthier
authors.forename: Guy
authors.initials: G
authors.lastname: Lanctôt
authors.forename: Jacynthe
authors.initials: J
authors.lastname: Saindon
authors.forename: Annick
authors.initials: A
authors.lastname: Vincent
authors.forename: Solange
authors.initials: S
authors.lastname: Gagnon
authors.forename: Angelo
authors.initials: A
authors.lastname: Tremblay
mesh_terms: D000328:Adult; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000453:epidemiology / Q000628:therapy; D010054:Brief Psychiatric Rating Scale; D015897:Comorbidity; D039721:Diagnostic and Statistical Manual of Mental Disorders; D015444:Exercise / Q000502:physiology*; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000175:diagnosis / Q000453:epidemiology; D009765:Obesity / Q000139:chemically induced* / Q000628:therapy*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy / Q000453:epidemiology; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents